Successful small-incision lenticule extraction for myopia

Article

Small-incision lenticule extraction for moderate to high myopia provides high rates of patient satisfaction, refractive predictability and is a safe procedure.

Small-incision lenticule extraction for moderate to high myopia provides high rates of patient satisfaction, refractive predictability and is a safe procedure.

Dr Anders Vestergaard et al., Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark, conducted a prospective clinical study on 144 patients with moderate to high myopia.

Small-incision lenticule extraction was performed with a femtosecond laser and manually extracted without flap creation. Each patient was treated and assessed for three months. One randomly selected eye of each patient was used for the statistical analyses.

Mean preoperative spherical equivalent was −7.18 D ± 1.57. In 40% of eyes with emmetropia as target refraction the uncorrected distance visual acuity was 0.1 logMAR or less one day postoperatively. This increased to 73% at three months postoperatively.

Mean corrected distance visual acuity (CDVA) significantly improved from -0.01 preoperatively to -0.03 three months postoperatively. Of the eyes studied, six lost one line of CDVA after three months and none of the eyes lost two lines or more of CDVA.

Achieved mean refraction was −0.09 ± 0.45 D from the attempted refraction. Out of the eyes included, 77% were within ±0.50 D and 95% were within ±1.00 D. As for patient satisfaction, 95% of the patients recommended the procedure to others.

To view the abstract visit the

Journal of Cataract and Refractive Surgery.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.